Nehmen Sie Kontakt auf.

Zur Kontaktliste

Haben Sie Fragen zu Services oder zum Literaturangebot von ZB MED? Benötigen Sie Tipps zur Recherche in LIVIVO?

Kontakt

info@zbmed.de
Telefonnummer: +49 (0)221 999 892 240

Köln

Medizin und Gesundheitswesen

Adresse:
ZB MED – Informationszentrum Lebenswissenschaften
Gleueler Straße 60
50931 Köln

Bonn

Ernährungs-, Umwelt- und Agrarwissenschaften

Adresse:
ZB MED – Informationszentrum Lebenswissenschaften
Friedrich-Hirzebruch-Allee 4
53115 Bonn

InfoCenter

INFORMATION.

WISSEN.
LEBEN.

Infrastruktur- und Forschungszentrum für lebenswissenschaftliche Daten und Informationen.

Thema Lebenswissenschaften?

Wir haben die Werkzeuge für Ihre passgenauen Recherchen.

Kongressdetails

30.11.2016 - 02.12.2016

AGAH e.V. INTRODUCTORY COURSE IN EXPLORATORY MEDICINES DEVELOPMENT, Part I

Veranstaltungsort
Oberursel
Kontakt und Ansprechparter

AGAH e.V. Association for Applied Human Pharmacology (AGAH) e.V.

Phone: +49 (0)170 78 444 38

e-Mail: info@agah.eu

www.agah.eu


Registration

CSi Hamburg GmbH

Goernestraße 30

20249 Hamburg (Germany)

Phone: +49 (0)40 30 770 300

Telefax: +49 (0)40 30 770 301

E-Mail: agah-meetings@csihamburg.de

Land
Deutschland
Kurzinfo

INTRODUCTION AND LEARNING OUTCOMES

This course addresses postgraduates in life sciences interested in early clinical development of medicinal products. Two training parts of 3 days each provide a concise overview on Human Pharmacology / Translational Medicine spanning from non-clinical pharmacology and toxicology over first-in-man studies to proof-of-concept clinical trials.

Learning Outcomes

On successful completion of Part 1, students should be able to demonstrate an understanding / knowledge of the following:

- principal steps in drug development – from compound selection to marketing application and beyond

- pertinent issues involved in the undertaking of early clinical research

- specific aspects of how to set-up and conduct early phase clinical trials

- regulation of medicines in Europe

- development and review of compound-specific information to ensure adherence to scientific, medical, ethical, and legal provisions

- integration of pertinent available scientific information into an IB and a clinical trial protocol

- principles of trial design, protocol submission and clinical conduct

- selection of appropriate trial population

- most common early phase clinical trials and their specific requirements

- assessment and evaluation of safety data from clinical trials

- relevance of formulation properties and in vitro characteristics of the trial medication for design and planning of an early phase clinical trial

- basics of pharmacokinetics

- defining pharmacokinetic (PK) endpoints for early phase clinical trials


Part II: 01 February - 03 February 2017